To see whether the activity of estrogen (ER) and progesterone (PR) receptors was related to the metabolism of 4PYR in breast cancer cells, we measured the concentrations of 4PYR and its derivatives after ER and PR antagonist treatment in T47D cells, which are characterized by the presence of both types of receptors. The gene discussed is ESR1; the disease is breast carcinoma.